Literature DB >> 10421269

Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: a pilot study.

P Menei1, M C Venier, E Gamelin, J P Saint-André, G Hayek, E Jadaud, D Fournier, P Mercier, G Guy, J P Benoit.   

Abstract

BACKGROUND: The authors have developed a new method of drug delivery into the brain using implantable biodegradable microspheres. In this study, this method was used to provide localized and sustained delivery of 5-fluorouracil (5-FU) after the surgical resection of glioblastoma. This antimetabolite and radiosensitizing drug was selected in an attempt to decrease the rate of local recurrence of the tumor.
METHODS: Eight patients with newly diagnosed glioblastoma were included in the study and 2 increasing amounts of 5-FU were studied (70 mg and 132 mg). After surgical resection of the tumor, poly(D-L lactide-co-glycolide) 5-FU-loaded microspheres with an average dimension of 45 microm were implanted in the wall of the surgical bed. External beam radiation (59.4 grays) was initiated before the seventh postsurgical day. Patients were followed by clinical examination, magnetic resonance imaging, and 5-FU assays in the blood and cerebrospinal fluid (CSF).
RESULTS: 5-FU assays confirmed sustained concentrations in the CSF for at least 1 month. Concentrations of 5-FU in the blood were lower and transitory. Systemic tolerance to the treatment was good; one case of recurrent brain swelling was observed at the higher dose studied. At the time of last follow-up the overall median survival time was 98 weeks from the time of implantation and 2 patients had achieved disease remission at 139 and 153 weeks, respectively.
CONCLUSIONS: This study demonstrates that biodegradable microspheres are efficient systems for drug delivery into the brain and may have future application in the treatment of brain tumors. Further studies are needed to confirm the potential of 5-FU-loaded microspheres for the radiosensitization of glioblastoma. [Please see editorial on pages 197-9, this issue].

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10421269

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  20 in total

Review 1.  Novel drug delivery strategies in neuro-oncology.

Authors:  Dani S Bidros; Michael A Vogelbaum
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

2.  Injectable chemotherapeutic microspheres and glioma II: enhanced survival following implantation into deep inoperable tumors.

Authors:  D F Emerich; S R Winn; P Snodgrass; D LaFreniere; M Agostino; T Wiens; H Xiong; R T Bartus
Journal:  Pharm Res       Date:  2000-07       Impact factor: 4.200

3.  Injectable chemotherapeutic microspheres and glioma I: enhanced survival following implantation into the cavity wall of debulked tumors.

Authors:  D F Emerich; S R Winn; Y Hu; J Marsh; P Snodgrass; D LaFreniere; T Wiens; B P Hasler; R T Bartus
Journal:  Pharm Res       Date:  2000-07       Impact factor: 4.200

4.  Paclitaxel-loaded polymeric microparticles: quantitative relationships between in vitro drug release rate and in vivo pharmacodynamics.

Authors:  Max Tsai; Ze Lu; M Guillaume Wientjes; Jessie L-S Au
Journal:  J Control Release       Date:  2013-09-20       Impact factor: 9.776

Review 5.  New delivery approaches for pediatric brain tumors.

Authors:  Ian F Pollack; Robert Keating
Journal:  J Neurooncol       Date:  2005-12       Impact factor: 4.130

6.  Lack of evidence of osteo-medullary metastases at diagnosis in patients with high grade gliomas.

Authors:  D Frappaz; A Jouvet; G S Pierre; F Giammarile; J Guyotat; R Deruty; E Jouanneau; D Ranchère-Vince
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

7.  Spray-dried poly(D,L-lactide) microspheres containing carboplatin for veterinary use: in vitro and in vivo studies.

Authors:  Elisabetla Gavini; Lucia Manunta; Stefano Giua; Giannina Achenza; Paolo Giunchedi
Journal:  AAPS PharmSciTech       Date:  2005-09-20       Impact factor: 3.246

8.  Daily low-dose carboplatin as a radiation sensitizer for newly diagnosed malignant glioma.

Authors:  K Peterson; G Harsh; P G Fisher; J Adler; Q Le
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

Review 9.  Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers.

Authors:  Christopher Guerin; Alessandro Olivi; Jon D Weingart; H Christopher Lawson; Henry Brem
Journal:  Invest New Drugs       Date:  2004-01       Impact factor: 3.850

10.  Sustained release chemotherapeutic microspheres provide superior efficacy over systemic therapy and local bolus infusions.

Authors:  Dwaine F Emerich; Pamela Snodgrass; Denise Lafreniere; Reginald L Dean; Heather Salzberg; Joanne Marsh; Brigido Perdomo; Mahin Arastu; Shelley R Winn; Raymond T Bartus
Journal:  Pharm Res       Date:  2002-07       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.